Ann: December 2020 Quarterly Activities Report and Appendix 4C, page-8

All well and good so far as delay with rollout. Covid definitely takes the priority. None of this will impact results of phase 2 results or Jansens possible contractural endorsement of Pro marker D. Therefore l remain very optomistic the SP will smash through the $1.00 dollar barrier in the next few months irrespective of delayed cash flow. Current retrace makes no material difference, probably just exposes more buying opportunity before the stock gets too expensive. Just my thoughts. Sit and hold, this is a no brainer medium term.